Treatment of Secondary Mitral Regurgitation in Heart Failure: A Shifting Paradigm in the Wake of the COAPT Trial | Zendy

Kelly Schlendorf | Zendy; Jared O’Leary | Zendy; JoAnn Lindenfeld | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Secondary Mitral Regurgitation in Heart Failure: A Shifting Paradigm in the Wake of the COAPT Trial

Author(s) -

Kelly Schlendorf,

Jared O’Leary,

JoAnn Lindenfeld

Publication year - 2020

Publication title -

us cardiology review

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.148

H-Index - 3

eISSN - 1758-390X

pISSN - 1758-3896

DOI - 10.15420/usc.2020.05

Subject(s) - mitraclip , medicine , mitral regurgitation , heart failure , cardiology , mitral valve repair , percutaneous , mitral valve , guideline , functional mitral regurgitation , intensive care medicine , ejection fraction , pathology

Mitral regurgitation (MR) is common in industrialized countries, with a prevalence of about 2% in the general population and about 9% in people over 75 years old. MR is classified as primary/degenerative when it results from a structural abnormality of the valve apparatus, or secondary/functional when it results from a disturbance of ventricular or annular geometry and/or function that impairs leaflet coaptation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research